A
Anne Banos
Researcher at University of Toulouse
Publications - 100
Citations - 3690
Anne Banos is an academic researcher from University of Toulouse. The author has contributed to research in topics: Lenalidomide & Population. The author has an hindex of 26, co-authored 87 publications receiving 3114 citations.
Papers
More filters
Journal ArticleDOI
Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial
Jesús F. San Miguel,Jesús F. San Miguel,Katja Weisel,Philippe Moreau,Martha Q. Lacy,Kijoung Song,Michel Delforge,Lionel Karlin,Hartmut Goldschmidt,Anne Banos,Albert Oriol,Adrian Alegre,Christopher T. Chen,Michele Cavo,Laurent Garderet,Valentina Ivanova,Joaquin Martinez-Lopez,Andrew R. Belch,Antonio Palumbo,Steve Schey,Pieter Sonneveld,Xiaoyan Yu,Lars Sternas,Christian Jacques,Mohamed H. Zaki,Meletios A. Dimopoulos +25 more
TL;DR: Pomalidomide plus low-dose dexamethasone, an oral regimen, could be considered a new treatment option in patients withRefractory or relapsed and refractory multiple myeloma.
Journal ArticleDOI
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma
Lotfi Benboubker,Meletios A. Dimopoulos,Angela Dispenzieri,John Catalano,Andrew Belch,Michele Cavo,Antonello Pinto,Katja Weisel,Heinz Ludwig,Nizar J. Bahlis,Anne Banos,Mourad Tiab,Michel Delforge,Jamie Cavenagh,Catarina Geraldes,Je-Jung Lee,Christine Chen,Albert Oriol,Javier de la Rubia,Lugui Qiu,Darrell White,Daniel Binder,Kenneth C. Anderson,Jean Paul Fermand,Philippe Moreau,Michel Attal,Robert Knight,Guang Chen,Jason Van Oostendorp,Christian Jacques,Annette Ervin-Haynes,Hervé Avet-Loiseau,Cyrille Hulin,Thierry Facon +33 more
TL;DR: Continuous lenalidomide-dexamethasone given until disease progression was associated with a significant improvement in progression-free survival, with an overall survival benefit at the interim analysis, among patients with newly diagnosed multiple myeloma who were ineligible for stem-cell transplantation.
Journal ArticleDOI
Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome-positive ALL
Philippe Rousselot,marie Magdelaine Coude,Nicola Gökbuget,Carlo Gambacorti Passerini,Sandrine Hayette,Jean-Michel Cayuela,Françoise Huguet,Thibaut Leguay,Patrice Chevallier,Celia Salanoubat,Caroline Bonmati,Magda Alexis,Mathilde Hunault,Sylvie Glaisner,Philippe Agape,Christian Berthou,Eric Jourdan,José Fernandes,Laurent Sutton,Anne Banos,Oumedaly Reman,Bruno Lioure,Xavier Thomas,Norbert Ifrah,Marina Lafage-Pochitaloff,Anne Bornand,Laure Morisset,Valérie Robin,Heike Pfeifer,André Delannoy,Josep M. Ribera,Renato Bassan,Marc Delord,Dieter Hoelzer,Hervé Dombret,Oliver G. Ottmann +35 more
TL;DR: Dasatinib combined with low-intensity chemotherapy was well-tolerated and gave long-term survival in 36% of elderly patients with Ph(+) ALL and monitoring of BCR-ABL1(T315I) from diagnosis identified patients with at high risk of early relapse and may help to personalize therapy.
Journal ArticleDOI
Final analysis of survival outcomes in the phase 3 FIRST trial of up-front treatment for multiple myeloma
Thierry Facon,Meletios A. Dimopoulos,Angela Dispenzieri,John Catalano,Andrew Belch,Michele Cavo,Antonello Pinto,Katja Weisel,Heinz Ludwig,Nizar J. Bahlis,Anne Banos,Mourad Tiab,Michel Delforge,Jamie D. Cavenagh,Catarina Geraldes,Je-Jung Lee,Christine Chen,Albert Oriol,Javier de la Rubia,Darrell White,Daniel Binder,Jin Lu,Kenneth C. Anderson,Philippe Moreau,Michel Attal,Aurore Perrot,Bertrand Arnulf,Lugui Qiu,Murielle Roussel,Eileen M Boyle,Salomon Manier,Mohamad Mohty,Hervé Avet-Loiseau,Xavier Leleu,Annette Ervin-Haynes,Guang Chen,Vanessa Houck,Lotfi Benboubker,Cyrille Hulin +38 more
TL;DR: Treatment with Rd continuous significantly improved survival outcomes vs MPT, supporting Rd continuous as a standard of care for patients with transplant-ineligible multiple myeloma.
Journal ArticleDOI
Long-Term Analysis of the IFM 99 Trials for Myeloma: Cytogenetic Abnormalities [t(4;14), del(17p), 1q gains] Play a Major Role in Defining Long-Term Survival
Hervé Avet-Loiseau,Michel Attal,Loïc Campion,Denis Caillot,Cyrille Hulin,Gerald Marit,Anne-Marie Stoppa,Laurent Voillat,Marc Wetterwald,Brigitte Pegourie,Eric Voog,Mourad Tiab,Anne Banos,Jérôme Jaubert,Didier Bouscary,Margaret Macro,Brigitte Kolb,Catherine Traullé,Claire Mathiot,Florence Magrangeas,Stephane Minvielle,Thierry Facon,Philippe Moreau +22 more
TL;DR: All patients with newly diagnosed multiple myeloma should be evaluated for these three chromosomal changes, not only to define high-risk patients but also to identify those with a longer life expectancy.